- Home
- ZURA vs INO Comparison
ZURA vs INO Comparison
Compare ZURA & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | INO |
|---|---|---|
| Founded | 2022 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 136.6M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | ZURA | INO |
|---|---|---|
| Price | $3.51 | $1.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $11.38 | $9.00 |
| AVG Volume (30 Days) | 408.9K | ★ 1.3M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $182,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,751.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.97 | $1.30 |
| 52 Week High | $4.68 | $4.61 |
Technical Indicators
Market Signals| Indicator | ZURA | INO |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 43.48 |
| Support Level | $3.57 | $1.76 |
| Resistance Level | $3.95 | $2.10 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 0.43 | 51.28 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.